ACCESS

This site gives you access to a set of useful materials that will remind you and your patients about the warnings and precautions relating to tofacitinib and appropriate actions to take.

Please confirm you are a healthcare professional

Prescriber brochure

The prescriber brochure provides succinct but comprehensive guidance on all important aspects of prescribing tofacitinib: therapeutic indications and contraindications; dosage; administration; monitoring; laboratory parameters; precautions and warnings; patient counseling; reporting of adverse events as well as a summarised risk management plan.

Patient alert card

This pocket-sized leaflet is designed for patients so they can carry important safety information with them. It summarises the safety information patients should understand before starting treatment with tofacitinib. It also describes what they should look out for during treatment and when to contact their doctor if they have any concerns or problems related to treatment.

Tofacitinib prescriber treatment initiation checklist

This leaflet is provided to remind prescribers about risks associated with the use of tofacitinib and the recommended steps to take before the first dose is administered

Tofacitinib prescriber treatment maintenance checklist

This provides prescribers with a checklist of treatment risks to monitor while patients are being treated with tofacitinib and the recommended tests to perform during treatment.

Patient information leaflet

This information leaflet is provided for patients who have been prescribed tofacitinib and presents key information about correct use and advice on actions to take to ensure they achieve optimal outcomes.

Summary of product characteristics

The tofacitinib summary of product characteristics (SmPC) provides information for healthcare professionals on how to use a medicine safely and effectively. It is updated as new efficacy or safety data emerge.

To obtain printed materials described here, please contact Pfizer’s Local Representative, Vivian Corporation Ltd.: +356 22588600.

 

To report suspected adverse reactions, please contact promptly Pfizer Hellas S.A. Medical Information at +30 210 67 85 800.

 

Any suspected adverse reactions in association with the use of XELJANZ, can also be reported via the national reporting system, to ADR Reporting

www.medicinesauthority.gov.mt/adrportal.

Malta Medicines Authority Sir Temi Żammit Buildings,

Malta Life Sciences Park,

San Ġwann,

SĠN 3000,

Malta Website: www.medicinesauthority.gov.mt/adrportal,

e-mail: [email protected].

 

Date of preparation: 02/2018

XELZ-MT-WEB, V1.0